Scintigraphic visualization of ocular melanoma with Tc-99m glutathione

1997 ◽  
Vol 11 (2) ◽  
pp. 143-146 ◽  
Author(s):  
Ahmet Tutuş ◽  
Kuddusi Erkiliç ◽  
Meral T. Ercan ◽  
Olgun Kontaş ◽  
Mehmet Aydin ◽  
...  
Keyword(s):  
Ocular Melanoma

Collaborative Ocular Melanoma Study Group

1999 ◽  
Vol 8 (1) ◽  
pp. 11-a-12
Author(s):  
S. L. Fine
Keyword(s):  
Ocular Melanoma ◽  
Study Group

scholarly journals Histone lactylation drives oncogenesis by facilitating m6A reader protein YTHDF2 expression in ocular melanoma

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Jie Yu ◽  
Peiwei Chai ◽  
Minyue Xie ◽  
Shengfang Ge ◽  
Jing Ruan ◽  
...  
Keyword(s):  
Macrophage Polarization ◽  
Regulation Of Gene Expression ◽  
Metabolic Stress ◽  
Ocular Melanoma ◽  
Rna Modifications ◽  
M1 Macrophage ◽  
Melanoma Therapy

Abstract Background Histone lactylation, a metabolic stress-related histone modification, plays an important role in the regulation of gene expression during M1 macrophage polarization. However, the role of histone lactylation in tumorigenesis remains unclear. Results Here, we show histone lactylation is elevated in tumors and is associated with poor prognosis of ocular melanoma. Target correction of aberrant histone lactylation triggers therapeutic efficacy both in vitro and in vivo. Mechanistically, histone lactylation contributes to tumorigenesis by facilitating YTHDF2 expression. Moreover, YTHDF2 recognizes the m6A modified PER1 and TP53 mRNAs and promotes their degradation, which accelerates tumorigenesis of ocular melanoma. Conclusion We reveal the oncogenic role of histone lactylation, thereby providing novel therapeutic targets for ocular melanoma therapy. We also bridge histone modifications with RNA modifications, which provides novel understanding of epigenetic regulation in tumorigenesis.

Risk of ocular melanoma in relation to cutaneous and IRIS naevi

1995 ◽  
Vol 60 (5) ◽  
pp. 622-626 ◽  
Author(s):  
Veronique Bataille ◽  
Peter Sasieni ◽  
Jack Cuzick ◽  
John L. Hungerford ◽  
Anthony Swerdlow ◽  
...  
Keyword(s):  
Ocular Melanoma

scholarly journals Response of an ocular melanoma to subconjunctival injection of 5-Thio-D-glucose or cis-platin

1987 ◽  
Vol 55 (5) ◽  
pp. 499-502 ◽  
Author(s):  
KA Skov ◽  
C Kumi ◽  
J Rootman ◽  
N Bussanich ◽  
MO Fellenz
Keyword(s):  
Ocular Melanoma ◽  
Subconjunctival Injection

Overexpression of hepatocyte growth factor and an oncogenic CDK4 variant in mice alters corneal stroma morphology but does not lead to spontaneous ocular melanoma

2016 ◽  
Vol 26 (1) ◽  
pp. 89-91 ◽  
Author(s):  
Marta M. Kilian ◽  
Martina C. Herwig ◽  
Frank G. Holz ◽  
Thomas Tüting ◽  
Karin U. Loeffler
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Corneal Stroma ◽  
Ocular Melanoma ◽  
Hepatocyte Growth

Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 9510-9510
Author(s):  
Jonathan S. Zager ◽  
Marlana Orloff ◽  
Pier Francesco Ferrucci ◽  
Evan Scott Glazer ◽  
Aslam Ejaz ◽  
...  
Keyword(s):  
Hepatic Metastases ◽  
Ideal Body Weight ◽  
Standard Of Care ◽  
Ocular Melanoma ◽  
Phase Iii ◽  
Point Estimate ◽  
Phase Iii Trial ◽  
Kaplan Meier ◽  
Independent Review ◽  
Phase Iii Study

9510 Background: Ocular melanoma, the most common intraocular malignancy, frequently metastasizes to the liver but to date there is no established standard of care for hepatic-dominant ocular melanoma patients. The FOCUS trial began as a randomized, phase III trial (301) comparing PHP with best alternative care (BAC). The trial was subsequently amended (301A) to remove the BAC arm due to enrollment concerns. Methods: Eligible patients with hepatic-dominant ocular melanoma were randomized 1:1 to receive PHP or BAC (investigator’s choice of TACE, pembrolizumab, ipilimumab, or dacarbazine) on the 301 trial. All eligible patients received PHP on the 301A trial. PHP patients could receive up to 6 PHP treatments, repeated every 6-8 weeks with melphalan dosed at 3.0mg/kg ideal body weight (IBW). Patients with progressive disease (PD) were discontinued from study treatment and all patients are followed until death. Patientswere imaged every 12 (±2) weeks until PD. The primary endpoint, ORR (per RECIST 1.1) as assessed by Independent Review Committee, will be characterized by the point estimate and 95% CI for each group (PHP and BAC). Categorical efficacy variables will be presented as frequency counts and percentages and 95% CI. Time-to-event variables will be summarized using Kaplan-Meier methods (median and 95% CI). Results: 144 patients were enrolled overall; 102 were assigned to PHP (301: n=43; 301A: n=59) and 42 were assigned to BAC. 91 PHP patients received treatment (301: n=40; 301A: n=51) and 32 BAC patients received treatment. At the time of this analysis, 4 PHP patients were still ongoing on study treatment with a minimum follow-up of 24 weeks. 79 PHP-treated patients and 29 BAC-treated patients were evaluable for response. ORR among PHP patients was 32.9% (26/79; 95% CI: 22.75-40.40%). ORR among BAC patients was 13.8% (4/29; 95% CI: 3.89-31.66%). The median PFS was 9.03 months (95% CI: 6.24-11.83) among PHP patients and was 3.06 months (95% CI: 2.69-5.65) among BAC patients; this difference was statistically significant ( p=0.0004). Among the 94 patients assessed for safety after treatment with PHP, 40.4% of patients experienced a serious treatment-emergent adverse event, the majority of which were hematological and resolved without sequelae. There were no treatment related deaths in the trial. Conclusions: In this analysis of preliminary data from the FOCUS trial, PHP demonstrates a statistically superior ORR and significantly prolonged PFS in comparison with BAC in the treatment of hepatic metastases from ocular melanoma. The data is encouraging as efficacious treatments for hepatic metastases from ocular melanoma are desperately needed. These early data show an improvement over the previous phase III study in terms of both efficacy (ORR and PFS) as well as toxicity using second generation filters. Clinical trial information: NCT02678572.

Sign in / Sign up

Export Citation Format

Share Document